Kelun scores sac-TMT win in first-line NSCLC population missing from Merck’s massive phase 3 program
The clinical blueprint for Merck & Co.’s prized TROP2-directed antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), ...
Programmed death ligand 1 (PD-L1) immunohistochemistry has become a cornerstone in the diagnostic pathway of non-small cell lung cancer (NSCLC), guiding the use of anti-PD-1/PD-L1 therapies. By ...
The Phase 3 results are the first direct proof-of-concept for an ADC replacing platinum-based chemo in a first-line ...
When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...
The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone ...
Real-world incidence and clinical outcomes of trastuzumab/pertuzumab-induced thrombocytopenia in adjuvant HER2-positive breast cancer: 8-year retrospective ...
Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non–small cell lung cancer. This is an ASCO Meeting Abstract from the 2025 ...
The first clinical case presents a 58-year-old female never-smoker with persistent cough, mild dyspnea, and new right-sided ...
Kelun-Biotech, listed under stock code 6990.HK, announced its Phase III OptiTROP-Lung06 trial of sac-TMT combined with ...
Investor's Business Daily on MSN
Can Dow Jones' Merck nab $25 billion with its smart bomb for cancer?
Merck stock popped Wednesday on the back of positive test results for a new treatment combo in a common form of lung cancer.
Background: As the use of immune checkpoint inhibitors in postoperative adjuvant chemotherapy for patients with programmed death-ligand 1 (PD-L1)-expressing lung cancer has been increasing, it is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results